Journal
ANTIVIRAL RESEARCH
Volume 132, Issue -, Pages 141-148Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.antiviral.2016.06.003
Keywords
MERS-CoV; Receptor-binding domain; Humanized monoclonal antibody; Protection; Treatment; Lethal infection
Categories
Funding
- China National Program of Infectious Disease fund [2014ZX10004001004]
- NIH [R21AI109094]
- intramural fund of the New York Blood Center [NYB000348]
Ask authors/readers for more resources
Middle East respiratory syndrome coronavirus (MERS-CoV) is continuously spreading and causing severe and fatal acute respiratory disease in humans. Prophylactic and therapeutic strategies are therefore urgently needed to control MERS-CoV infection. Here, we generated a humanized monoclonal antibody (mAb), designated hMS-1, which targeted the MERS-CoV receptor-binding domain (RBD) with high affinity. hMS-1 significantly blocked MERS-CoV RBD binding to its viral receptor, human dipeptidyl peptidase 4 (hDPP4), potently neutralized infection by a prototype MERS-CoV, and effectively cross neutralized evolved MERS-CoV isolates through recognizing highly conserved RBD epitopes. Notably, single-dose treatment with hMS-1 completely protected hDPP4 transgenic (hDPP4-Tg) mice from lethal infection with MERS-CoV. Taken together, our data suggest that hMS-1 might be developed as an effective immunotherapeutic agent to treat patients infected with MERS-CoV, particularly in emergent cases. (C) 2016 The Authors. Published by Elsevier B.V.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available